Peroxisome proliferator-activated receptor gamma PPARG) Pro12Ala: Lack of association with weight gain in psychiatric inpatients treated with olanzapine or clozapine

Molecular Diagnosis and Therapy

Volumn 16, Issue 2, 2012, Pages 93-98

  Staeker, Julia ^a   Leucht, Stefan ^a   Steimer, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotics; Clozapine; Olanzapine; PPAR gamma target; Single nucleotide polymorphism targets; Weight gain

Indexed keywords

AMITRIPTYLINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOMETHIAZOLE; CLOMIPRAMINE; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXEPIN; GABAPENTIN; LAMOTRIGINE; LEVOTHYROXINE; LITHIUM; METFORMIN; MIRTAZAPINE; OLANZAPINE; OMEPRAZOLE; OXCARBAZEPINE; PANTOPRAZOLE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM IODIDE; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; ZIPRASIDONE; ZOLPIDEM; ZOPICLONE;

ACUTE PSYCHOSIS; ADJUSTMENT DISORDER; ADULT; AGED; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT; DELUSIONAL DISORDER; DEPRESSION; DISEASE ASSOCIATION; EATING DISORDER; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSESSIVE COMPULSIVE DISORDER; PERSONALITY DISORDER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN;

EID: 84859791325     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Littrell KH, Petty RG, Wolf NM. Olanzapine: a 5-year perspective. Expert Rev Neurother 2006 Jun; 6 (6): 811-21 (Pubitemid 43961883)
2. Reynolds GP, Zhang ZJ, Zhang XB. Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism. Lancet 2002 Jun 15; 359 (9323): 2086-7 (Pubitemid 34680975)
3. Zhang JP, Malhotra AK. Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 2011 Jan; 7 (1): 9-37
4. Sicard MN, Zai CC, Tiwari AK, et al. Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. Pharmacogenomics 2010 Nov; 11 (11): 1561-71
5. Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A2.1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2009 Feb; 10 (1): 20-9
6. Ellingrod VL, Bishop JR, Moline J, et al. Leptin and leptin receptor gene polymorphisms and increases in body mass index (BMI) from olanzapine treatment in persons with schizophrenia. Psychopharmacol Bull 2007; 40 (1): 57-62
7. Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferatoractivated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002 Nov 2; 360 (9343): 1410-8 (Pubitemid 35341309)
8. Yang Z, Yin JY, Gong ZC, et al. Evidence for an effect of clozapine on the regulation of fat-cell derived factors. Clin Chim Acta 2009 Oct; 408 (1-2): 98-104
9. Yang LH, Chen TM, Yu ST, et al. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 2007 Sep; 56 (3): 202-8
10. Herken H, Erdal M, Aydin N, et al. The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia. DNA Cell Biol 2009 Oct; 28 (10): 515-9
11. Kang SH, Lee J, Chang AK, et al. Genetic polymorphisms in the HTR2C and peroxisome proliferator-activated receptors are not associated with metabolic syndrome in patients. Psychiatry Investig 2011 Sep; 8 (3): 262-8
12. Gouda HN, Sagoo GS, Harding AH, et al. The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol 2010 Mar 15; 171 (6): 645-55
13. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998 Nov; 20 (3): 284-7 (Pubitemid 28507675)
14. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001 Apr; 62 (4): 231-8 (Pubitemid 32428761)
15. Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011 Dec 1; 25 (12): 1035-59
16. Masud S, Ye S. Effect of the peroxisome proliferator activated receptorgamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003 Oct; 40 (10): 773-80 (Pubitemid 37311078)
17. Saxena R, Voight BF, Lyssenko V, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007 Jun 1; 316 (5829): 1331-6 (Pubitemid 46871653)
18. Adkins DE, Aberg K, McClay JL, et al. Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 2011 Mar; 16 (3): 321-32
19. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005 Nov; 19 (6 Suppl.): 16-27 (Pubitemid 44567855)
20. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000 Jun; 157 (6): 975-81 (Pubitemid 30412350)
21. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999 Jun; 60 (6): 358-63 (Pubitemid 29289721)
22. Leadbetter R, Shutty M, Pavalonis D, et al. Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992 Jan; 149 (1): 68-72